Back to Search
BRUCE HILLNER, M.D.
M.D.
Internal Medicine Physician
NPI: 1295825834Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
0101037449(VA)
Research & Publications (20)
The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry.
PMID 19016303·Cancer·2009
8-other
ACP Journal Club. Risk for breast cancer declined after postmenopausal hormone therapy was stopped.
PMID 19528556·Ann Intern Med·2009
8-other
Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry.
PMID 18997054·J Nucl Med·2008
8-other
Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.
PMID 18362365·J Clin Oncol·2008
4-observational
The National Oncologic PET Registry (NOPR): design and analysis plan.
PMID 17942807·J Nucl Med·2007
8-other
Annual mammographic screening beginning at 40 years of age did not significantly reduce breast cancer mortality after 10 years in women.
PMID 17537879·Evid Based Med·2007
8-other
Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
PMID 16177989·Cancer·2005
4-observational
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
PMID 15368322·Cancer·2004
8-other
Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center.
PMID 15483025·J Clin Oncol·2004
8-other
Trends in clinical trials reports in common cancers between 1989 and 2000.
PMID 12721263·J Clin Oncol·2003
1-meta
Burden of illness associated with metastatic melanoma: an audit of 100 consecutive referral center cases.
PMID 11335908·Cancer·2001
8-other
Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma.
PMID 11169930·Cancer·2001
3-trial
Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease.
PMID 11544579·Semin Oncol·2001
6-review
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care.
PMID 10829054·J Clin Oncol·2000
6-review
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.
PMID 10623695·J Clin Oncol·2000
8-other
The role of bisphosphonates in metastatic breast cancer.
PMID 11034635·Semin Radiat Oncol·2000
6-review
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
PMID 10735895·J Clin Oncol·2000
3-trial
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
PMID 10715310·J Clin Oncol·2000
6-review
Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing.
PMID 19332715·J Clin Oncol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1250 E MARSHALL ST
RICHMOND, VA 23298 - Phone
- (828) 512-9804
Quick Facts
- NPI
- 1295825834
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile